DWC Issues Bulletin Suspending Certain Provisions and Rules Due to COVID-19

Commissioner Brown has issued a new bulletin on COVID-19 as it relates to the Texas workers' compensation system. Here are some of the items covered in the new bulletin:

• work search compliance standards for supplemental income benefits;
• testing, training, application, and recertification requirements for designated doctors; and
• required medical exams.

View the full bulletin on the TDI website.

DWC Operations Update in Response to COVID-19

Commissioner Brown sends an update to system participants about changes in DWC’s operations in response to COVID-19. Read more at https://bit.ly/2QIbQQm.

The move to telehealth will make it easier for providers to prescribe an opioid or other controlled substance during the COVID-19 public health emergency.

March 18, 2020 - Telemedicine has found yet another key purpose during the coronavirus public health emergency: the prescribing of controlled substances, such as opioids.

Per new clarification from the US Department of Justice Drug Enforcement Agency (DEA), healthcare professionals can now prescribe a controlled substance to a patient using telehealth technology.

This announcement comes in the wake of the public health emergency declared by HHS Secretary Alex Azar on January 31, 2020.

Telemedicine for Worker’s Compensation

Telehealth is a great tool in battling the spread of infections. Texas workers’ compensation allows for billing and reimbursement of certain telemedicine and telehealth services in place of regular on-site medical care. Ask your doctor about services they might provide.

NCHS Data Brief No. 356, January 2020

PDF Versionpdf icon (423 KB)

Holly Hedegaard, M.D., Arialdi M. Miniño, M.P.H., and Margaret Warner, Ph.D.

The American Medical Association on Tuesday awarded former Texas State Rep. John Zerwas, MD, its Dr. Nathan Award for Outstanding Government Service.

Dr. Zerwas, an anesthesiologist from Richmond, served in the Texas House of Representatives from 2007 to 2019. He stepped down in September to become The University of Texas System’s new executive vice chancellor for health affairs.

“A physician, an advocate, and a citizen-legislator, Dr. Zerwas has served the citizens and patients of Texas with distinction,” AMA Board Chair Jesse M. Ehrenfeld, MD, said in a statement. “As a legislator, he stood on principle, and put science and evidence first when fighting for public health, his constituents, and the people of Texas. For his outstanding work and leadership, the AMA is pleased to present Dr. John M. Zerwas with the Nathan Davis Award.”

READ MORE

Insurance Carrier Scorecards Now Online

Workers' compensation system and individual insurance carrier scorecards with year-to-date performance information can now be viewed online. The scorecards provide summary information related to complaints, timely reporting and payment of initial temporary income benefits, and timely reporting of medical bills and reconsideration medical bills.

The scorecard is on the TDI website.

Agency Action Plan to Address Substance Use

Substance use is a complex problem with devastating and lasting effects across the lifespan. It strains our families, it ravages our communities, and threatens the well-being of our entire state. While opioids are still cause for concern, recent trends on the use of methamphetamines, marijuana, other illicit drugs, and alcohol cannot be ignored.

As the state agency entrusted with improving the health, safety, and well-being of Texas, DSHS is committed to addressing substance use.

READ MORE

Addiction Medicine Fellowship (AMF) Program

NOTICE OF FUNDING OPPORTUNITY (HRSA-20-013)
Fiscal Year 2020 Application Due Date: February 25, 2020

The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year 2020 Addiction Medicine Fellowship (AMF) Program. The application cycle closes on February 25, 2020.

Please note that modifications have been made to the original Notice of Funding Opportunity. Download the latest version before applying.

Register for February Designated Doctor Training

Below is an excerpt from an article published on January 15, 2020 in the Texas Society of Anesthesiologist Newsletter: 

On the Shoulders of Giants: Legends of Texas Anesthesiology Gabor B. Racz, M.D., ChB, DABPM, FIPP

Grover E. Murray Professor

Researchers at Johns Hopkins Hospital reported that patients treated with buprenorphine for opioid use disorder show surprisingly significant improvements in adhering to medications for other chronic unrelated conditions.

Published in the journal Medical Care (2019;57[9]:667-672), the population-based, retrospective study reviewed medical records for more than 12,000 patients with a diagnosis of opioid use disorder (OUD) who were given buprenorphine, a partial opioid agonist widely used to treat OUD. Expanded use of buprenorphine is linked with the national epidemic of opioid misuse. In 2016, approximately 700,000 Americans filled buprenorphine prescriptions—more than double the number 10 years earlier. However, a recent study found disparities in access to the medication. The rate of Medicaid-covered prescriptions for buprenorphine was much lower in states that did not expand their Medicaid programs in accordance with the Affordable Care Act.

READ MORE